Impax Laboratories Inc

Impax Laboratories — J.P. Morgan Healthcare Conference 2011

30 slides from Impax Laboratories's conference presentation, Jan 11, 2011

  1. Slide 1: J.P. Morgan Healthcare Conference

    Slide 1: J.P. Morgan Healthcare Conference

    J.P. Morgan Healthcare Conference January 10, 2011 Larry Hsu - President & CEOArt Koch - Chief Financial Officer ....Improving Health Through Technology

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of ma

  3. Slide 3: Strong Platform for Long Term Growth

    Slide 3: Strong Platform for Long Term Growth

    3 3 Strong Platform for Long Term Growth Unique Targeted High Value ANDAs Offering Long-Term Growth Drivers Generic Brand Drug Delivery Expertise Product Development Formulation Technology Core Competency

  4. Slide 4: Dual Strategic Focus

    Slide 4: Dual Strategic Focus

    4 Dual Strategic Focus Unique targeted ANDAsFirst-to-file, First-to-marketLimited competitionDifficult to formulate and manufacture36 apps pending at FDA62 under development Improve on marketed CNS products505(b)(2) NDA candidatesDevelop IP positions2 products in Phase III1 product in Phase II

  5. Slide 5: A Leader in Generic Medicines

    Slide 5: A Leader in Generic Medicines

    ....A Leader in Generic Medicines

  6. Slide 6: Generic Growth Initiatives

    Slide 6: Generic Growth Initiatives

    6 Generic Growth Initiatives

  7. Slide 7: Internal Generic Development Expertise

    Slide 7: Internal Generic Development Expertise

    7 Internal Generic Development Expertise Sun/Taro KV Dr. Reddys Actavis/Abrika Sandoz/Lek Watson/Andrx Mylan Teva/Ivax/Barr 9 9 10 12 17 17 22 26 31 Solid position relative to peers Controlled Release Products Approved from 2001 to Dec 2010

  8. Slide 8: 2010 New ANDA Applications

    Slide 8: 2010 New ANDA Applications

    8 2010 New ANDA Applications Goal8 to 10 new ANDA applications2 to 3 of these First-to-File or First-to-Market opportunitiesResults to Date 2008 2009 2010 ANDA Filing Goal 10 10 10 Accepted for Filing 10 10 8 More to come... 2008 2009 2010 FTF/FTM Goal 2.5 2.5 2.5 FTF/FTM ANDAs 4 3 0 To be determine

  9. Slide 9: Products Pending or Under Development

    Slide 9: Products Pending or Under Development

    9 98 Products Pending or Under Development 43 Currently Marketed ANDAs 62 $14 BillionUnder Development 36 $19 BillionPending at FDA Present Future = 98 Products in Pipeline$33 Billion U.S. Brand/Generic Sales

  10. Slide 10: Disclosed ANDA Pending Pipeline

    Slide 10: Disclosed ANDA Pending Pipeline

    10 Disclosed ANDA Pending Pipeline Disclosed ANDA Pending Pipeline Disclosed ANDA Pending Pipeline Aware of additional lawsuits containing similar patent infringement claims and believes all filers of ANDAs submitted same date or within a certain period will be entitled to 180 days of exclusivity. 3

  11. Slide 11: Development Pipeline

    Slide 11: Development Pipeline

    11 Development Pipeline Total Under Development 62 $14B * Brands not yet launched or sales data not yet available Unique Targeted High Value ANDAs First-to-File/First-to-Market First-to-File/First-to-Market First-to-File/First-to-Market Focused on:

  12. Slide 12: Advancing CNS Treatment

    Slide 12: Advancing CNS Treatment

    ....Advancing CNS Treatment

  13. Slide 13: Impax Pharmaceuticals Background

    Slide 13: Impax Pharmaceuticals Background

    13 Impax Pharmaceuticals Background Therapeutic area focus: CNS - NeurologyDevelop products providing significant advancements in clinical outcomes Product differentiationLeveraging proven compounds to improved resultsFormulation expertise lays the foundationControlled-release formulation technologi

  14. Slide 14: Brand Growth Initiatives

    Slide 14: Brand Growth Initiatives

    Brand Growth Initiatives on R&D rograms Promotion For Collaborations in Pipeline Development & Commercialization Co-promotion “Driving to Financial Self-Support” @ IMPAX

  15. Slide 15: IPX066: Parkinson's Disease

    Slide 15: IPX066: Parkinson's Disease

    15 IPX066: Parkinson's Disease Major Market Prevalence (in millions) Affects as many as 1-2% of persons aged 60 and olderOver 2 million people in US, Europe and Japan$3+ billion global market Symptoms are motor and non-motor in nature

  16. Slide 16: IPX066 Potential Benefits

    Slide 16: IPX066 Potential Benefits

    16 IPX066 Potential Benefits... Reduction in "Off" time Reduced dosing frequency Continuous "On" time without troublesome dyskinesia Predictability of "On' time Targeted to address several limitations of current Levodopa therapy IPX066: Controlled-release Carbidopa/Levodopa ....Leading to Improvemen

  17. Slide 17: IPX066: Collaboration with GlaxoSmithKline

    Slide 17: IPX066: Collaboration with GlaxoSmithKline

    17 IPX066: Collaboration with GlaxoSmithKline Joint Development and Commercialization of IPX066Agreement reached in December 2010Overview of agreementGSK acquires commercial rights outside of the US & Taiwan Impax received $11.5 million upfront paymentImpax can receive additional milestones of up to

  18. Slide 18: IPX066: Development Status

    Slide 18: IPX066: Development Status

    18 Naive PatientsAPEX-PD COMPLETED Advanced PatientsADVANCE-PD Started September 2009Expect Data - Q2 2011Advanced Patients (CD-LD + entacapone)ASCEND-PD Expect Data End 2011 4Q 2011 IPX066: Development Status

  19. Slide 19: IPX066 - Naive PD Patient Phase III Study

    Slide 19: IPX066 - Naive PD Patient Phase III Study

    19 19 IPX066 - Naive PD Patient Phase III Study Phase III randomized, double-blind, placebo-controlled, fixed-dose, parallel arm study of 3 doses of IPX066 vs. placeboEnrolled subjects with early PDConducted under Special Protocol Assessment with FDANorth America and Europe30-week treatment duration

  20. Slide 20: APEX-PD Phase III - Met Primary & Secondary Endpoints

    Slide 20: APEX-PD Phase III - Met Primary & Secondary Endpoints

    20 (p<0.0001 for all treatments) (p<0.0001 for both measures at all three dose levels) APEX-PD Phase III - Met Primary & Secondary Endpoints Significant clinical improvementParkinson's disease symptoms (UPDRS)Clinician & Patient Reported outcomes Clinical & Patient Global Impressions of Change (CGI,

  21. Slide 21: IPX066 - Advanced PD Patient Phase III Study

    Slide 21: IPX066 - Advanced PD Patient Phase III Study

    21 21 IPX066 - Advanced PD Patient Phase III Study Phase III randomized, double-blind, active-control, parallel-group comparison of IPX066 vs. IR carbidopa-levodopaNorth America and Europe22-week treatment durationPrimary endpoint: percentage of "Off" time during waking hours Completed enrollment in

  22. Slide 22: IPX159: Phase IIa Study Results

    Slide 22: IPX159: Phase IIa Study Results

    23 IPX159: Phase IIa Study Results Efficacy Results Discomfort Improvement Efficacy Results Limb Movement Reduction IPX159 significantly improved discomfort by 49% compared to placebo at 60 minutes (p < 0.002) IPX159 significantly reduced limb movements compared to placebo (p = 0.002), which worsene

  23. Slide 23: IPX159: Safety Results & Development Strategy

    Slide 23: IPX159: Safety Results & Development Strategy

    24 IPX159: Safety Results & Development Strategy Safety Results Safety & tolerability appropriate for moderate to severe RLSMajority of adverse events were mild or moderate in severityDevelopment ActivitiesDevelop for moderate to severe RLS indicationIND filing planned for 1H 2011 Planning Phase IIb

  24. Slide 24: 2011 Financial Outlook

    Slide 24: 2011 Financial Outlook

    2011 Financial Outlook ....Improving Health Through Technology

  25. Slide 25: Strong Growth First Nine Months 2010

    Slide 25: Strong Growth First Nine Months 2010

    26 Strong Growth First Nine Months 2010 **Adjusted results which, among other adjusted items, primarily exclude the effect of a change in accounting for revenue under the Company's Strategic Alliance Agreement with Teva. Refer to reconciliation of GAAP to Non- GAAP at end of presentation.

  26. Slide 26: 2011 Financial Outlook

    Slide 26: 2011 Financial Outlook

    27 2011 Financial Outlook Top-line performance driven by generic division products:Variability depending on Generic Adderall XR(r)Supply issues and Shire litigationCitizen Petition status Gross margins expected in ~ 50% rangeExpense control is critical management objectiveFree cash flow positive

  27. Slide 27: 2011 Financial Outlook

    Slide 27: 2011 Financial Outlook

    28 2011 Financial Outlook 2011 Financial Outlook

  28. Slide 28: Strong Platform for Long Term Growth

    Slide 28: Strong Platform for Long Term Growth

    29 29 Strong Platform for Long Term Growth Unique Targeted High Value ANDAs Offering Long-Term Growth Drivers Generic Brand Drug Delivery Expertise Product Development Formulation Technology Core Competency

  29. Slide 29: GAAP to Non-GAAP Reconciliation

    Slide 29: GAAP to Non-GAAP Reconciliation

    30 GAAP to Non-GAAP Reconciliation Total revenues, cost of revenues, gross profit, gross profit margin, net income, EBITDA and earnings per diluted share excluding adjusted items are not measures of financial performance under generally accepted accounting principles (GAAP) and should not be constru

  30. Slide 30: GAAP to Non-GAAP Reconciliation

    Slide 30: GAAP to Non-GAAP Reconciliation

    31 GAAP to Non-GAAP Reconciliation (a) Material Modification to Teva AgreementIn July 2010, the Company entered into a material modification of its Strategic Alliance Agreement with Teva, and as a result the Company will apply the revised accounting standards of FASB ASC 605-25 Multiple Element Arra

Source: SEC EDGAR · 8-K filed Jan 11, 2011

More decks from Impax Laboratories Inc